Company intelligence / Profile preview
Equilibre Biopharmaceuticals
New York, New York, United Stateseqneuro.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
EQU-001 demonstrated positive Phase 2 results as an adjunctive therapy for focal seizures in adults with epilepsy, showing safety and tolerability at all tested doses through 60 mg QD with no treatment-related Serious Adverse Effects. A dose-dependent decrease in per 28-day focal seizure frequency was observed with a 35.7% median reduction over placebo in the 60 mg treatment arm[6].
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Equilibre Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equilibre Biopharmaceuticals.